Treatment of Persistent Pharyngeal Thrush

Initial Treatment Approach

The Infectious Diseases Society of America recommends fluconazole 100-200 mg daily for 7-14 days as the most effective first-line treatment for persistent pharyngeal thrush, with suppressive therapy using fluconazole 100 mg three times weekly recommended for patients with recurrent infections 1, 2
Topical therapy with clotrimazole troches (10 mg 5 times daily) or nystatin suspension (100,000 U/mL, 4-6 mL four times daily) for 7-14 days is appropriate for mild pharyngeal thrush, as suggested by the Clinical Infectious Diseases guidelines 1, 2
Miconazole mucoadhesive buccal tablets (50 mg once daily) applied to the mucosal surface over the canine fossa are equally effective as clotrimazole troches, according to the Clinical Infectious Diseases guidelines 1

The Clinical Infectious Diseases guidelines recommend fluconazole 100 mg three times weekly as long-term suppressive therapy for patients with recurrent pharyngeal thrush 1, 2
Antiretroviral therapy is strongly recommended to reduce the incidence of recurrent infections in HIV-infected patients, as suggested by the Clinical Infectious Diseases guidelines 1, 2
Suppressive therapy is particularly important for patients with persistent immunosuppression, especially HIV-infected patients with CD4 counts <50 cells/μL, according to the Clinical Infectious Diseases guidelines 1, 3

Itraconazole oral solution >200 mg daily achieves 64-80% response rates in fluconazole-refractory pharyngeal thrush, as reported by the Clinical Infectious Diseases guidelines 1, 3, 2
Posaconazole suspension 400 mg twice daily is efficacious in approximately 75% of refractory cases, according to the Clinical Infectious Diseases guidelines 1, 3, 2
Voriconazole 200 mg twice daily (oral or IV) is effective for fluconazole-refractory infections, as suggested by the Clinical Infectious Diseases guidelines 1, 4

Thorough disinfection of dentures in addition to antifungal therapy is essential for definitive cure of denture-related pharyngeal thrush, as recommended by the Clinical Infectious Diseases guidelines 1, 2, 4
Oropharyngeal fungal cultures are of little benefit as many individuals have asymptomatic colonization, and treatment frequently does not result in microbiological cure, according to the Praxis Medical Insights guidelines 2, 4
Azole-refractory infections are more common in patients with prior repeated azole exposure and severely immunocompromised patients, as reported by the Clinical Infectious Diseases guidelines 1, 3, 4